1. Home
  2. COGT vs NLOP Comparison

COGT vs NLOP Comparison

Compare COGT & NLOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • NLOP
  • Stock Information
  • Founded
  • COGT 2014
  • NLOP N/A
  • Country
  • COGT United States
  • NLOP United States
  • Employees
  • COGT N/A
  • NLOP N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • NLOP
  • Sector
  • COGT Health Care
  • NLOP
  • Exchange
  • COGT Nasdaq
  • NLOP Nasdaq
  • Market Cap
  • COGT 545.3M
  • NLOP 445.8M
  • IPO Year
  • COGT 2018
  • NLOP N/A
  • Fundamental
  • Price
  • COGT $4.81
  • NLOP $30.27
  • Analyst Decision
  • COGT Buy
  • NLOP Strong Buy
  • Analyst Count
  • COGT 7
  • NLOP 1
  • Target Price
  • COGT $14.00
  • NLOP $46.00
  • AVG Volume (30 Days)
  • COGT 1.3M
  • NLOP 74.7K
  • Earning Date
  • COGT 05-06-2025
  • NLOP 01-01-0001
  • Dividend Yield
  • COGT N/A
  • NLOP N/A
  • EPS Growth
  • COGT N/A
  • NLOP N/A
  • EPS
  • COGT N/A
  • NLOP N/A
  • Revenue
  • COGT N/A
  • NLOP $127,453,000.00
  • Revenue This Year
  • COGT N/A
  • NLOP N/A
  • Revenue Next Year
  • COGT N/A
  • NLOP N/A
  • P/E Ratio
  • COGT N/A
  • NLOP N/A
  • Revenue Growth
  • COGT N/A
  • NLOP N/A
  • 52 Week Low
  • COGT $3.72
  • NLOP $22.36
  • 52 Week High
  • COGT $12.61
  • NLOP $34.38
  • Technical
  • Relative Strength Index (RSI)
  • COGT 44.64
  • NLOP 54.01
  • Support Level
  • COGT $4.55
  • NLOP $29.97
  • Resistance Level
  • COGT $5.89
  • NLOP $30.88
  • Average True Range (ATR)
  • COGT 0.38
  • NLOP 0.65
  • MACD
  • COGT 0.09
  • NLOP 0.14
  • Stochastic Oscillator
  • COGT 34.55
  • NLOP 75.16

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About NLOP Net Lease Office Properties of Beneficial Interest

Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.

Share on Social Networks: